Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sana Biotechnology Inc SANA

Healthcare Biotechnology
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product... see more

Recent & Breaking News (NDAQ:SANA)

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2023

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

GlobeNewswire December 1, 2023

Sana Biotechnology to Present at November and December 2023 Investor Conferences

GlobeNewswire November 21, 2023

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

PR Newswire November 21, 2023

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

GlobeNewswire November 17, 2023

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

GlobeNewswire November 9, 2023

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 8, 2023

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

GlobeNewswire November 2, 2023

Flagship Pioneering Launches Pioneering Intelligence

PR Newswire November 1, 2023

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

GlobeNewswire October 10, 2023

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

PR Newswire September 11, 2023

Sana Biotechnology to Present at September 2023 Investor Conferences

GlobeNewswire August 30, 2023

Invaio achieves first registration for citrus greening solution featuring Trecise(TM) technology

PR Newswire August 29, 2023

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire August 3, 2023

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

GlobeNewswire June 16, 2023

Sana Biotechnology to Present at June 2023 Investor Conferences

GlobeNewswire May 31, 2023

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

PR Newswire May 16, 2023

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

GlobeNewswire May 8, 2023

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

GlobeNewswire May 8, 2023